FDA proposes to remove ephedrine OTC status citing abuse, misuse concerns.
This article was originally published in The Tan Sheet
Executive Summary
EPHEDRINE WITHDRAWAL FROM OTC STATUS PROPOSED BY FDA in a July 27 Federal Register notice. FDA said the notice of proposed rulemaking was issued "in response to a request from the U.S. Department of Justice's Drug Enforcement Administration to restrict OTC availability of ephedrine" because of its use in the illicit manufacturing of controlled substances such as methamphetamine and methcathinone, and due to the potential for misuse and abuse of OTC ephedrine drug products.
You may also be interested in...
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register
OTC Bronchodilators With Ephedrine Permitted In New Proposed Rule
Additional warnings and other revised labeling would be required for bronchodilator products containing ephedrine or epinephrine under an FDA proposed rule published in the July 13 Federal Register